10x Genomics, Inc. Class A Common Stock (TXG) — Analysis Summary
10x Genomics, Inc. Class A Common Stock (TXG) has a market cap of $9.80B with year-over-year revenue growth of +5.2%. Net margin stands at -6.8%. The stock trades at a P/E ratio of -130.4.
Key Takeaways
- Revenue changed +5.2% year-over-year
- Net margin of -6.8%
- P/E ratio of -130.4
Compared to other companies in the LABORATORY ANALYTICAL INSTRUMENTS sector, TXG posted revenue growth of +5.2% and trades at a P/E of -130.4.
10x Genomics, Inc. Class A Common Stock (TXG)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -29461.3x — earnings do not cover interest payments
Operating margin at -14.3% — material operating losses
Net income fell 72.5% vs the prior period.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Employees
1,178
Headquarters
PLEASANTON, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.